Insmed (NASDAQ:INSM) Coverage Initiated by Analysts at Rothschild & Co Redburn

Rothschild & Co Redburn assumed coverage on shares of Insmed (NASDAQ:INSM) in a report released on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $263.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on INSM. JPMorgan Chase & Co. boosted their price target on Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. The Goldman Sachs Group boosted their target price on Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Morgan Stanley upped their target price on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Jefferies Financial Group lifted their price target on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Finally, UBS Group upped their price objective on shares of Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Twenty equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average price target of $187.89.

Insmed Stock Performance

INSM stock opened at $205.04 on Thursday. The firm has a 50 day moving average of $179.16 and a two-hundred day moving average of $133.54. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75. The company has a market capitalization of $43.73 billion, a price-to-earnings ratio of -33.12 and a beta of 1.01. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) EPS. As a group, equities analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider owned 36,461 shares of the company’s stock, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the sale, the insider directly owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. This trade represents a 33.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 233,650 shares of company stock valued at $41,063,785 in the last three months. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Insmed

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after buying an additional 2,291,328 shares during the period. Norges Bank bought a new position in shares of Insmed during the 2nd quarter worth about $194,728,000. Adage Capital Partners GP L.L.C. boosted its position in shares of Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after acquiring an additional 1,799,382 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new stake in Insmed in the second quarter valued at about $153,389,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.